CME: Immunocellular Therapies for Relapsed/Refractory Heme Malignancies: A Focus on CAR T-Cell Therapy

Immunocellular Therapies for Relapsed/Refractory Heme Malignancies: A Focus on CAR T-Cell Therapy

Immunocellular Therapies for Relapsed/Refractory Heme Malignancies: A Focus on CAR T-Cell Therapy
RestartResume
Join oncology experts as they discuss new therapies and clinical data, and how this can be incorporated into practice.

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    The treatment of relapsed or refractory leukemias and lymphomas continues to be challenging, often characterized by limited therapeutic options and poor outcomes. Effective new therapies are needed for these patients.

    Chimeric antigen receptor (CAR) T-cell therapy represents a radical departure from current treatments by simultaneously being cell therapy, gene therapy, and immunotherapy. It promises to revolutionize the treatment of multiple hematologic malignancies, including relapsed or refractory B-cell acute lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and others.

    This activity will review CAR T-cell therapy’s biologic rationale and mechanism of action, the latest efficacy and safety data in different patient populations, and how to effectively manage potentially severe toxicities to maximize patient outcomes.

    This activity is a web-based, on-demand activity, featuring an expert panel discussion. This activity is designed as a forum for the debate and evaluation of the most recent clinical data, and to provide evidence-based updates and expert insights on the discussion points to translate current and emerging evidence into real-world clinical practice.

  • Faculty

    Jae Park, MD
    Assistant Attending Physician
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Robert Mocharnuk, MD
    Professor of Hematology/Oncology,
    Department of Medicine
    Southern Illinois University School of Medicine
    Springfield, Illinois

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Identify the biologic rationale for the development of CAR T-cell therapies and their mechanisms of action in the treatment of relapsed/refractory hematologic malignancies
    • Evaluate recent clinical trial data regarding the efficacy and safety of CAR T-cell therapies in relapsed/refractory lymphoma and leukemia
    • Implement individualized treatment plans using CAR T-cell therapy based on current clinical evidence and patient and disease characteristics
    • Discuss best practices and supportive care algorithms for preventing and managing toxicities associated with CAR T-cell therapy
  • Target Audience

    This activity is intended for hematologists, oncologists, nurses, and other healthcare professionals who manage and treat B-cell malignancies.

  • Disclosure of Conflicts of Interest

    AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity. Jae Park, MD, reported a financial interest/relationship or affiliation in the form of Consultant, Adaptive Biotechnologies, Amgen, Inc, Novartis Pharmaceuticals Corp, Pfizer, Inc, Shire, TG Therapeutics, Inc.; Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck. 

    The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity. The following planners and managers, Linda Gracie-King, MS; Jocelyn Timko; and Marilyn Haas, PhD, RN, CNS, ANP-BC hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.  

  • Accreditation and Credit Designation Statements

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Credit Designation for Physicians

    AXIS Medical Education designates this live activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Nursing

    AXIS Medical Education designates this continuing nursing education activity for 0.25 contact hours.

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    AXIS Contact Information

    For information about the certification of this activity, please contact AXIS at info@axismeded.com

  • Commercial Support

    This activity is supported by educational grants from Kite Pharma, Inc. and Novartis Pharmaceuticals.

  • Terms of Use

    Disclosure of Unlabeled Use

    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Method of Participation and Request for Credit

    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. 

    There is no fee for this educational activity. 

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

NEW FEATURES:

Register

Join the Global Oncology Academy of learners.
Registration is free and easy.

Register Now